IOSR Journal Of Pharmacy And Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 14, Issue 4 Ser. II (Jul – Aug 2019), PP 18-21
www.Iosrjournals.Org

Newer Approches of the Ocular Drug Delivery System: An Overview

Aakashsinh vaghela*, Dr.Pragneshpatni
A-One Pharmacy College, Snme Campus, Enasan,Ahmedabad
Corresponding Author: Aakashsinh Vaghela

Abstract: *Ideal ophthalmic drug delivery is one of the most interesting and challenging problem facing the pharmaceutical companies in the market .and the major problem associated with the conventional dosage forms is the bioavailability of drug. The Poor bioavailability of ophthalmic solutions caused by dilution and drainage from the eye can be overcome by using in-situ-forming ophthalmic drug delivery systems. To overcome these problems various types of dosage forms such as nanoparticles, liposomes and microemulsions have been developed.Controlleddrugdelivery systems offer many advantages overconventionaldosage forms interms of improving drug bioavailability, reducing toxicity and decreasing dosage frequency. Ocular drug delivery has seen several advances in the past few decades, with respect to new drugs, improved formulations, targeted delivery, as well as exploration of new routes of drug administration. and New materials have been explored for encasing existing drugs, which can enhance treatment by increasing bioavailability, decreasing toxicity, providing better tissue adherence, targeted delivery as well as increased duration of action.Eye is the most select organ of the body and different medication conveyance frameworks are utilized to convey tranquilize into eye yet there are different impediments. and to enhance visual medication contact time, bioavailability and to decrease the patient distress, recurrence of measurements, and additionally to back off the end of the medication there are concentrating towards more up to date tranquilize conveyance frameworks for ophthalmic organization.*

KeyWords:*Ocular drug delivery, eye drug delivery,nanotechnology, Nano- formulation, Ocular Disorder,punctum plugs.*

Date of Submission: 13-07-2019 Date of acceptance: 29-07-2019

I. Introduction

A newer approach for ocular drug delivery systems are being explored to develop extended duration and controlled release strategy. These reviews focus briefly on different drug delivery systems for ocular therapy along with their safety evaluation of ocular drug delivery formulations case studies.Ocular disposition and elimination of a therapeutic agent is dependent upon its physicochemical properties as well as the relevant ocular anatomy and physiology. These improvement of more up to date, more delicate demonstrative procedures and helpful operators renders direness to the advancement of greatest fruitful and advanced ocular drug delivery systems. Eyeas an entryway for medication conveyance is by and large utilized for the neighborhood treatment as against systemic treatment with a specific end goal to maintain a strategic distance from the danger of eye harm from high blood groupings of medication which are not planned for eye. The conventional ocular dosage forms are eye drops, eye ointments, eye gels, eye solutions, eye injections, eye irritation solutions, eye suspensions, sol to gel systems. The most widely used are eye drops, eye ointments and gels, which constitute 80% of the total ophthalmic preparations. Successful treatment of visual ailments is a ghastly test for researchers in the field, particularly as a result of the way of infections and nearness of the visual boundaries particularly in back visual portions. In order to remove the constraints placed by these conventional ocular therapies. A newer approach for ocular drug delivery systems are being explored to develop extended duration and controlled release strategy. and These reviews focus briefly on different drug delivery systems for ocular therapy along with their safety evaluation of ocular drug delivery formulations case studies.

Structure of Eye:



Composition of Eye:

1. The eye comprises of a few sections that take after a camera.
2. Sclera - The eye's white external defensive coat, typically observed as the "white of the eye" Cornea - the straightforward, bended structure at the front of the eye
3. Iris - the shaded part of the eye - blue, cocoa, green, dim and so on - that can be seen through the cornea.
4. Pupil - the dark part of the eye amidst the iris. It contracts or widens as indicated by the measure of light going through it.
5. lens - the straightforward circle (with both sides being raised) promptly behind the iris and student.
6. Aqueous silliness- The straightforward liquid (with consistency like water) that courses behind the cornea and before the focal point.
7. Vitreous silliness - The material (like straightforward jam) that fills the eyeball between the focal point and the retina.
8. Retina - the light-touchy layer of a large number of nerve cells that line the back of the eyeball. The phones comprise of two principle bunches, called bars and cones because of their appearance under the magnifying instrument.
9. Rods - increasingly various, spread out over the whole retina with additional toward external edge, react to low levels of light.
10. Cones - far less, focused around the retina's inside, react to shading and to subtle elements. Macula - the little focal point of the retina, in charge of perusing vision.
11. Retinal shade epithelium - This is a dim hued layer of cells at the back of the retina in charge of giving oxygen and different supplements to the poles and cones.
12. Choroid - an expansive system of veins that vehicle oxygen and different supplements to the retinal color cells.
13. Optic circle - a little yellow oval structure in the retina, to which nerve cell associations go from every one of the poles and cones.
14. Optic nerve and past - the "string" of nerve cell associations that go from the eyeball to goals all through the mind.[1]

Function:

- When a light goes from that protest the cornea, then goes through the fluid cleverness, focal point and vitreous amusingness to achieve the retina.
- During this entry, the light gets to be distinctly engaged onto the macula. At the macula, the light cause's concoction responses in the cones, that subsequently send electrical messages from the eye to the cerebrum.
- The mind perceives these messages and demonstrates to you that this specific protest has been seen.
- The cones are hence in charge of you having the capacity to perceive hues and to peruse.
- The bars are fundamental for you to find oblivious, and to identify items to the sides, above and underneath the protest on which you are straightforwardly engaged.
- This work keeps you from catching snags when moving around.
- All the retinal cells (bars and cones) are given oxygen and different supplements from the retinal shade cells (epithelium), which are kept provided by the rich system of veins in the choroid.

Route of Drug Administration:

There are a few conceivable routes of drug delivery into the ocular tissues. The determination of the route of administration depends essentially on the target tissue.



- **Topical Route**: Regularly topical visual medication organization is expert by eye drops, yet they have just a short contact time on the eye surface. The contact, and along these lines' length of medication activity, can be delayed by plan outline (e.g. gels, gel, balms, and additions).
- **Subconjunctival Route:** subconjunctival infusions have been utilized to convey drugs at expanded levels to the uvea. Presently thismethod of medication conveyance has increased new energy for different reasons. The advance in materials sciences and pharmaceutical plan have given new energizing conceivable outcomes to create controlled discharge details to convey medications to the back fragment and to direct the mending procedure after surgery.
- **Intravitreal Route:** Direct medication organization into the vitreous offers particular preferred standpoint of more clear access to the vitreous and retina. It ought to be noted. however, that conveyance from the vitreous to the choroid is more muddled because of the deterrent by the RPE (Retinal Shade Epithelium) boundary. Little atoms can diffuse quickly in the vitreous however the portability of substantial particles, especially emphatically charged, is limited. [(2)]

Advance Drug Delivery System:

- **Stem cell Therapy:** The most successful ocular application has been the utilization of limbal undifferentiated cells, transplanted from a source other than the patient for the reestablishment of corneal epithelium. The wellsprings of limbal cells incorporate benefactors, auto grafts, corpse eyes, and (as of late) cells developed in culture. Undifferentiated cell Therapy has shown incredible accomplishment for specific diseases of the front section.
- **Sclera Plug therapy:**The Sclera plug can be embedded utilizing a basic strategy at the standards plane district of eye, and made of biodegradable polymers and medications, and it step by step discharges compelling measurements of medications for a while upon biodegradation. The fittings are viable for regarding vitreoretinal illnesses, for example,proliferative vitreoretinopathy; cytomegalovirus retinitis reacts to rehashed intravitreal infusions and for vitreoretinal issue that require vitrectomy.
- **Particulates (Nanoparticles and Microparticles):** The greatest size cut-off for micro particles for ophthalmic organization is around 5-10 mm. Nanoparticles are readied utilizing bio adhesive polymers to give managed impact to the captured drugs. That is the reason microspheres and nanoparticles are promising medication transporters for ophthalmic application.
- **Nano-formulations in ocular drug therapy:** Nano-formulations have been brought into the field of ophthalmology in order to increase the bioavailability and therapeutic index of the drugs and thereby hopes of bettering the chances of patient's recovery. Various forms of Nano-formulations that haspote.

Recent Developments in Ophthalmic Drug Delivery:

- ✓ The Most conventional ophthalmic dosage forms are simplistic. and It is usual that water-soluble drugs are delivered through topical administration in an aqueous solution, and water-insoluble drugs are administered

topically. The major deficiencies of these conventional dosage forms include poor ocular drug bioavailability.

- ✓ a lack of effective systems for drug delivery to the posterior segment of ocular tissue. Poor ocular drug bioavailability is the result of ocular anatomical and physiological constraints, which include the relative impermeability of the corneal epithelial membrane, tear dynamics, nasolacrimal drainage, and the high efficiency of the blood–ocular barrier.
- ✓ Ocular drug delivery is one of the most fascinating and challenging tasks facing the Pharmaceutical researchers. One of the major barriers of ocular medication is to obtain and maintain a therapeutic level at the site of action for prolonged period of time.
- ✓ The eye drop dosage form is easy to install but suffers from the inherent drawback that most of the instilled volume is eliminated from the pre-corneal area resulting in a bioavailability ranging from 1-10% of total administrated dose. The poor bioavailability and rapid pre-corneal elimination of drugs given in eye drops is mainly due to conjunctival absorption, rapid solution drainage by gravity, induced lachrymation, blinking reflex, low corneal permeability and normal tear turnover.
- ✓ Because of poor ocular bioavailability, many ocular drugs are applied in high concentrations. This cause both ocular and systemic sideeffects, which is often related to high peak drug concentrations in the eye and in systemic circulation. The frequent periodic instillations of eye drops are necessary to maintain a continuous sustained therapeutic drug level. This gives the eye a massive and unpredictable dose of medication.[8-11]

II. Conclusion:

Novel ocular drug delivery systems like nanoparticles and Nano micelles face a major challenge for technology transfer and large-scale manufacturing. Nanotechnology has a high clinical translatable potential for treating various ophthalmic disorders. They can have the capacity to replace traditional ophthalmic medications in the near future. Parallel efforts not only in novel product development but also for product scale-up are required is the need of the hour.

Reference:

[1]. Wolff, E: Anatomy of eye and orbit. Blakistone Company, New York and Toronto, 4th edition, 1954:207.
[2]. K. P. Sampath Kumar, Debit Bhowmik, G. Harish, S. Duraivel, B. Pragathi Kumar: Ocular Inserts: A Novel Controlled Drug Delivery System. The pharma innovation journal 2013; 1(12): 1-16.
[3]. VHL Lee: New directions in the optimization of ocular drug delivery. Journal ofOculPharmakon 1990; 6:157–164.
[4]. Kaur IP, Kanwar M: Ocular preparations: The formulation approach. Drug developmentIndustrial Pharmacy 2002; 28(5):473-493.
[5]. VHL Lee, JR Robinson. Review: Topical drug delivery: recent developments and future challenges. Journal Oculus Pharmakon. 1986; 2:67–108.
[6]. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP.: Nanocarriers in ocular drug delivery: Current Pharmaceutical Design 2009; 15: 2724-2750.
[7]. Chien YW. Ocular drug delivery and delivery systems. In: Novel drug delivery systems. Edn 2, Marcel Dekker, New York, 1992, 269
[8]. Peyman, GA and Ganiban, GJ Adv. Drug Deliv. Rev., 1995, 16, 107–123.
[9]. Katz, I. M., Shaped ophthalmic inserts for treating dry eyes syndrome. U.S. Patent. 1982; 4,343,787.
[10]. Lee, V.H.L., and Robinson, J.F., "Review: Topical ocular drug delivery; recent developments and future challenges". J. Ocul. Pharmakon., 1976; 2: 67.
[11]. Saettone, M.F., and Salminen, L., "Ocular inserts for topical delivery". Advanced drug delivery reviews, 1995; 16(1): 95.
[12]. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmic. Vis. Sci. 2000; 41: 1181-1185.
[13]. A.Urtti, L.Salminen, minimizing systemic absorption of topically administered ophthalmic drugs, Surv, Ophthalmol. 37(1993)
[14]. K.C. Swan, The use of methylcellulose in ophthalmology, Arch. Ophthalmol. 33 (1945).
[15]. O.Dudinski, B.C. Finnin, B.L. Reed, Acceptability of thickened eye drops to human subjects, Curr.Ther.Res.33 (1983).
[16]. Noriyuki K and Shinobu F. Recent Advances in Ocular Drug Delivery Systems, Polymers 2011; 3.
[17]. Sugar HS, Riazi A, Schaffner R. The bulbar conjunctival lymphatics and their clinical significance. Trans. Am. Acad. Ophthalmol. Otolaryngology. 1957; 61.
[18]. Gausas R.E., Gonnering R.S, Lemke BN, Dortzbach RK., Sherman DD. Identification of human orbital lymphatics. Ophthal. Plast. Reconstr. Surg. 1999; 15.
[19]. Singh, D. Conjunctival lymphatic system. J. Cataract. Refract. Surg. 2003, 29, 632-633.
[20]. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 2000; 41: 1181-1185.

Aakashsinh Vaghela" Newer Approches of the Ocular Drug Delivery System: An Overview"IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) 14.4 (2019): 18-21.